Aura Biosciences, Inc.
Aura Biosciences, Inc. (Nasdaq: AURA) is a clinical-stage biotechnology company developing precision therapies designed to treat solid tumors while preserving organ function. The company's website is www.aurabiosciences.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Aura Biosciences, Inc. does
In the company’s own words
Aura Biosciences, Inc. (Nasdaq: AURA) is a clinical-stage biotechnology company developing precision therapies designed to treat solid tumors while preserving organ function. The company's website is www.aurabiosciences.com.
Aura's lead candidate, belzupacap sarotalocan (bel-sar), represents a novel class of drugs called virus-like drug conjugates (VDCs) that employ a dual mechanism of action. The therapeutic approach combines acute tumor cell killing through light-activated cytotoxic payload delivery with activation of secondary immune-mediated responses that generate long-term antitumor immunity. Bel-sar consists of modified human papillomavirus-derived capsid proteins conjugated to light-activated molecules, enabling precise tumor cell elimination with minimal damage to surrounding healthy tissue.
The company is advancing bel-sar through late-stage clinical development across multiple oncology indications. In ocular oncology, bel-sar is in a global Phase 3 trial for early choroidal melanoma, the most common primary malignant intraocular tumor affecting approximately 11,000 patients annually in the United States and Europe. The company has also received Orphan Drug Designation and Fast Track Designation from the FDA for this indication. Additionally, bel-sar is in Phase 2 development for metastases to the choroid and Phase 1 proof-of-concept testing for cancers of the ocular surface.
In urologic oncology, Aura is developing bel-sar for non-muscle-invasive bladder cancer (NMIBC), which represents a significant unmet medical need affecting approximately 80,000 patients annually in the United States. The company announced positive Phase 1 data in 2025 and is currently conducting a Phase 1b/2 trial evaluating additional doses and treatment regimens in intermediate and high-risk NMIBC patients. Bel-sar has received Fast Track Designation from the FDA for bladder cancer treatment.
Aura's strategy focuses on completing its Phase 3 choroidal melanoma trial and pursuing FDA approval, expanding development in additional ocular oncology indications, advancing bladder cancer development, and building operational capabilities for potential commercialization. The company operates with a management team experienced in biopharmaceutical development and commercialization across oncology and ophthalmology sectors.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1501796
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Aura Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Aura Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Aura Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Aura Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Aura Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”